Lonza and Antharis Therapeutics enter target-specific licence agreement

Inhibrx's ozekibart BLA accepted by FDA for chondrosarcoma treatment

Sensei Biotherapeutics changes name to Faeth Therapeutics

AstraZeneca secures US approval for Truqap combination in PTEN‑deficient prostate cancer

Acousia Therapeutics reports positive top-line efficacy results for ACOU085 in cisplatin-induced ototoxicity

Menarini reports Phase 3 data for selinexor plus ruxolitinib in myelofibrosis

Roche secures IVDR approval to expand VENTANA MMR RxDx Panel indications

Guardant Health expands FDA-approved companion diagnostic use for HERNEXEOS

PharmaEssentia expands North American footprint with acquisition of Canadian partner FORUS Therapeutics

FDA grants priority review for Genentech's Tecentriq in stage III dMMR/MSI-H colon cancer

Harbour BioMed IND for HBM7004 accepted by China's NMPA

FDA grants rare paediatric disease designation to RedHill's opaganib

GSK to acquire Nuvalent for USD10.6bn to expand lung cancer portfolio

Adcentrx Therapeutics' ADRX-0405 granted Chinese regulatory IND clearance to treat late-stage solid tumours

Curasight reports encouraging preliminary Phase 1 data for uTREAT in glioblastoma